Risk of abducens nerve palsy following COVID-19 vaccination.
J AAPOS
; 28(2): 103867, 2024 04.
Article
in En
| MEDLINE
| ID: mdl-38458601
ABSTRACT
PURPOSE:
To investigate the prevalence and risk of new-onset abducens nerve palsy and acute-onset diplopia following mRNA COVID-19 vaccination.METHODS:
In this retrospective, population-based study, patient data from the COVID-19 Research Network of TriNetX was searched via the TriNetX Analytics platform for patients who received specific vaccinations based on Common Procedural Technology codes. We recorded instances of newly diagnosed abducens nerve palsy and diplopia within 21 days following each vaccination event.RESULTS:
Of the 3,545,224 patients (mean age at vaccination, 46.2 ± 21.3 years) who received the mRNA COVID-19 vaccine, 12 (<0.0001%) patients had a new diagnosis of abducens nerve palsy and 453 (0.013%) had acute-onset diplopia within 21 days of first dose of COVID-19 vaccination. After propensity score matching, the relative risk for new abducens nerve palsy diagnosis after the first dose of COVID-19 vaccination was not significantly different from that after influenza (RR, 0.77), Tdap (RR, 1.0), or the second dose of the COVID-19 vaccinations (RR, 1.00). Furthermore, there was a lower risk of abducens nerve palsy diagnosis after the first dose of the COVID-19 vaccination compared with the risk after COVID-19 infection (RR, 0.15).CONCLUSIONS:
The risk of a new abducens nerve palsy diagnosis following the first dose of the COVID-19 vaccine is lower than the risk associated with COVID-19 infection itself. There is no evidence to suggest a causal relationship between COVID-19 vaccination and the development of abducens nerve palsy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Abducens Nerve Diseases
/
COVID-19 Vaccines
/
COVID-19
Limits:
Humans
Language:
En
Journal:
J AAPOS
Journal subject:
OFTALMOLOGIA
/
PEDIATRIA
Year:
2024
Document type:
Article